These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

112 related items for PubMed ID: 29985882

  • 1. Bleeding in the Post-operative Oculoplastic Patient on Novel Anticoagulants.
    Joganathan V.
    Ophthalmic Plast Reconstr Surg; 2018; 34(4):397. PubMed ID: 29985882
    [No Abstract] [Full Text] [Related]

  • 2. Retroperitoneal haematoma in a postoperative ALIF patient taking rivaroxaban for atrial fibrillation.
    Deekonda P, Stokes OM, Chan D.
    Eur Spine J; 2019 Apr; 28(4):688-692. PubMed ID: 27807780
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Risk Factors for Major Bleeding in Rivaroxaban Users With Atrial Fibrillation.
    Tamayo SG, Simeone JC, Nordstrom BL, Patel MR, Yuan Z, Sicignano NM, Peacock WF.
    J Am Coll Cardiol; 2016 Sep 06; 68(10):1144-6. PubMed ID: 27585515
    [No Abstract] [Full Text] [Related]

  • 7. Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation.
    Yao X, Abraham NS, Sangaralingham LR, Bellolio MF, McBane RD, Shah ND, Noseworthy PA.
    J Am Heart Assoc; 2016 Jun 13; 5(6):. PubMed ID: 27412905
    [Abstract] [Full Text] [Related]

  • 8. Comparison of the Incidence of Major Bleeding With Rivaroxaban Use Among Nonvalvular Atrial Fibrillation Patients With Versus Without Diabetes Mellitus.
    Peacock WF, Tamayo S, Sicignano N, Hopf KP, Yuan Z, Patel M.
    Am J Cardiol; 2017 Mar 01; 119(5):753-759. PubMed ID: 28081941
    [Abstract] [Full Text] [Related]

  • 9. Gastrointestinal Safety of Direct Oral Anticoagulants: A Large Population-Based Study.
    Abraham NS, Noseworthy PA, Yao X, Sangaralingham LR, Shah ND.
    Gastroenterology; 2017 Apr 01; 152(5):1014-1022.e1. PubMed ID: 28043907
    [Abstract] [Full Text] [Related]

  • 10. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
    Maura G, Blotière PO, Bouillon K, Billionnet C, Ricordeau P, Alla F, Zureik M.
    Circulation; 2015 Sep 29; 132(13):1252-60. PubMed ID: 26199338
    [Abstract] [Full Text] [Related]

  • 11. [Pruritus and rivaroxaban].
    Aguilar-Shea AL, Gallardo-Mayo C.
    Semergen; 2018 Sep 29; 44(4):e96-e97. PubMed ID: 29439912
    [No Abstract] [Full Text] [Related]

  • 12. Spontaneous splenic rupture due to rivaroxaban.
    Nagaraja V, Cranney G, Kushwaha V.
    BMJ Case Rep; 2018 Mar 05; 2018():. PubMed ID: 29507024
    [Abstract] [Full Text] [Related]

  • 13. [Real life clinical management of nonvalvular atrial fibrillation: results from the Italian epidemiological survey eXperience on the use of rivaroxaban].
    Colonna P, Ammirati F, a nome del Gruppo Italiano eXperience.
    G Ital Cardiol (Rome); 2016 Nov 05; 17(11):932-939. PubMed ID: 27996999
    [Abstract] [Full Text] [Related]

  • 14. Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation.
    Piccini JP, Hellkamp AS, Washam JB, Becker RC, Breithardt G, Berkowitz SD, Halperin JL, Hankey GJ, Hacke W, Mahaffey KW, Nessel CC, Singer DE, Fox KA, Patel MR.
    Circulation; 2016 Jan 26; 133(4):352-60. PubMed ID: 26673560
    [Abstract] [Full Text] [Related]

  • 15. Meta-analysis of risk of stroke and thrombo-embolism with rivaroxaban versus vitamin K antagonists in ablation and cardioversion of atrial fibrillation.
    Nairooz R, Sardar P, Pino M, Aronow WS, Sewani A, Mukherjee D, Paydak H, Maskoun W.
    Int J Cardiol; 2015 Jan 26; 187():345-53. PubMed ID: 25839640
    [Abstract] [Full Text] [Related]

  • 16. [Good efficacy and safety profile in clinical practice].
    MMW Fortschr Med; 2015 Nov 19; 157(20):66-7. PubMed ID: 26977521
    [No Abstract] [Full Text] [Related]

  • 17. Incremental economic burden associated with major bleeding among atrial fibrillation patients treated with factor Xa inhibitors.
    Deitelzweig S, Neuman WR, Lingohr-Smith M, Menges B, Lin J.
    J Med Econ; 2017 Dec 19; 20(12):1217-1223. PubMed ID: 28760063
    [Abstract] [Full Text] [Related]

  • 18. Rivaroxaban-induced hemorrhagic pericardial tamponade in end-stage renal disease.
    Rapista N, Sarkar S, Chaudhary R.
    J Thromb Thrombolysis; 2020 Nov 19; 50(4):982-983. PubMed ID: 32495012
    [No Abstract] [Full Text] [Related]

  • 19. CHA2DS2-VASc Scores and Major Bleeding in Patients With Nonvalvular Atrial Fibrillation Who Are Receiving Rivaroxaban.
    Peacock WF, Tamayo S, Patel M, Sicignano N, Hopf KP, Yuan Z.
    Ann Emerg Med; 2017 May 19; 69(5):541-550.e1. PubMed ID: 27913059
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.